Bank of New York Mellon Corp Raises Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

Bank of New York Mellon Corp lifted its holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) by 8.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 75,174 shares of the company’s stock after purchasing an additional 6,051 shares during the period. Bank of New York Mellon Corp owned approximately 0.15% of scPharmaceuticals worth $266,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its stake in shares of scPharmaceuticals by 116.9% in the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after acquiring an additional 3,101 shares in the last quarter. Captrust Financial Advisors raised its holdings in shares of scPharmaceuticals by 32.2% in the 3rd quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock valued at $85,000 after purchasing an additional 4,513 shares in the last quarter. Rhumbline Advisers lifted its position in shares of scPharmaceuticals by 20.1% during the 4th quarter. Rhumbline Advisers now owns 42,554 shares of the company’s stock worth $151,000 after purchasing an additional 7,112 shares during the last quarter. MetLife Investment Management LLC increased its holdings in scPharmaceuticals by 135.0% in the third quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock valued at $77,000 after buying an additional 9,752 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in scPharmaceuticals in the third quarter valued at $46,000. 89.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on SCPH shares. Maxim Group dropped their price objective on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a report on Thursday, March 20th.

scPharmaceuticals Trading Down 8.6 %

NASDAQ:SCPH opened at $2.78 on Friday. The company has a market capitalization of $139.79 million, a PE ratio of -1.46 and a beta of 0.40. scPharmaceuticals Inc. has a 52-week low of $2.72 and a 52-week high of $5.65. The stock’s 50 day moving average price is $3.23 and its 200 day moving average price is $3.70. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66.

scPharmaceuticals (NASDAQ:SCPH) last announced its earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The business had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.08 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. On average, research analysts anticipate that scPharmaceuticals Inc. will post -1.53 EPS for the current year.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.